<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04760691</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00203162</org_study_id>
    <secondary_id>R01AI145675</secondary_id>
    <nct_id>NCT04760691</nct_id>
  </id_info>
  <brief_title>Pre-Exposure Prophylaxis (PrEP)- Gender Affirming Hormone Therapy (GAHT) Interactions in TGW</brief_title>
  <official_title>A Phase I Trial for the Evaluation of the Two-way Pharmacokinetic-pharmacodynamic (PD) Interaction of Gender Affirming Exogenous Estrogen (With Testosterone Suppression) on TDF/FTC PrEP in Transgender Women (TGW)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a research study to determine the best way to dose Truvada®, an oral medication&#xD;
      licensed to be taken as Pre-Exposure Prophylaxis (PrEP) to prevent HIV infection, in&#xD;
      transgender women who are also taking feminizing hormones. The duration of the study is about&#xD;
      4 months, and involves a screening visit, a baseline visit with colon biopsies and kidney&#xD;
      function testing, and several outpatient visits, including 5 intensive sampling visits that&#xD;
      last about 9 hours and involve colon biopsies, kidney function testing and other blood&#xD;
      specimen collections.&#xD;
&#xD;
      After the baseline visit, participants will start on PrEP, daily Truvada® pills, and will&#xD;
      continue on the Truvada® for 5 weeks. Participants will then receive either an injection of&#xD;
      Lupron, oral low-dose estradiol or oral high-dose estradiol, which will be taken along with&#xD;
      the Truvada® PrEP for 1-2 weeks before returning for an intensive sampling visit.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The PrEP-GAHT Interactions in TGW protocol is a phase 1, open label study to compare the&#xD;
      safety, PK and PD of five sequential phases of PrEP administration in the presence or absence&#xD;
      of testosterone-reducing therapies or dose-escalated estrogen therapy. Each participant will&#xD;
      undergo a Screening Visit to evaluate eligibility.&#xD;
&#xD;
      Following Baseline evaluation, eligible participants will receive 300 milligrams (mg) TDF/200&#xD;
      mg FTC (Truvada®) once daily for seven days, using direct observation approaches, to achieve&#xD;
      steady state drug PrEP concentrations. After one week of therapy, participants will undergo&#xD;
      intensive PK analysis as well as collection of colorectal biopsies for PD testing (PK1).&#xD;
      During the PK-intensive day, iohexol will be administered intravenously for the empirical&#xD;
      determination of renal function and measured glomerular filtration rate (mGFR). While&#xD;
      concurrently on PrEP, participants will then be intramuscularly administered depot leuprolide&#xD;
      acetate (11.25 mg Lupron®). Two weeks post-injection, when testosterone concentrations are&#xD;
      far below the lower limit of normal of total testosterone in men (typically &lt; 200 ng/dL, or &lt;&#xD;
      2 ng/mL), sampling for PK, PD, and renal function will be performed (PK2).&#xD;
&#xD;
      Participants will then immediately begin low-dose oral estrogen therapy (1 mg 17β-estradiol)&#xD;
      in conjunction with PrEP for one week, at which time samples will be collected for the&#xD;
      analyses described above (PK3). While still on PrEP, participants will then transition to&#xD;
      high-dose estrogen therapy (6 mg 17β-estradiol) for the remainder of the study. One week&#xD;
      post-high dose estrogen therapy in the presence of PrEP, pharmacologic and renal samples will&#xD;
      be collected for analysis (PK4). PrEP will then be discontinued, and two weeks later, samples&#xD;
      will be collected to assess renal function and hormonal concentrations, and evaluate the&#xD;
      presence of any remaining PrEP in plasma, Peripheral Blood Mononuclear Cells (PBMC), or&#xD;
      colorectal tissue (though it should be near undetectable levels for most analytes according&#xD;
      to the investigators' prior data)(PK5).&#xD;
&#xD;
      Safety assessments, including history/physical, chemistry/hematology labs at screening and&#xD;
      interim history will be performed at each study-intensive visit. Additionally, periodic&#xD;
      assessments of gender dysphoria will be conducted at baseline and a convenient time during PK&#xD;
      visits throughout the study. To ensure compliance, participants will undergo direct&#xD;
      observation of dosing each day of the week prior to PK visits, using the aforementioned&#xD;
      strategies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Tenofovir plasma concentration</measure>
    <time_frame>Days 7-8, Days 21-22, Days 28-29, Days 35-36, Days 49-50</time_frame>
    <description>Change in Tenofovir plasma concentration measured in nanograms (ng) per milliliter (mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Tenofovir-Diphosphate PBMC concentration</measure>
    <time_frame>Days 7-8, Days 21-22, Days 28-29, Days 35-36, Days 49-50</time_frame>
    <description>Change in tenofovir-diphosphate (TFV-DP) PBMC concentration reported in femtomoles per million cells (fmol/million)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in TFV-DP colon tissue concentration</measure>
    <time_frame>Days 7-8, Days 21-22, Days 28-29, Days 35-36, Days 49-50</time_frame>
    <description>Change in TFV-DP colon tissue concentration reported in fmol/million</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in serum estradiol concentration</measure>
    <time_frame>Days 7, 21, 28, 35, 49</time_frame>
    <description>Change in serum estradiol reported in picograms (pg) per mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum free testosterone concentration</measure>
    <time_frame>Days 7, 21, 28, 35, 49</time_frame>
    <description>Serum free testosterone reported in nanograms per deciliter (ng/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum total testosterone concentration</measure>
    <time_frame>Days 7, 21, 28, 35, 49</time_frame>
    <description>Change in serum total testosterone reported in ng/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum luteinizing hormone (LH) concentration</measure>
    <time_frame>Days 7, 21, 28, 35, 49</time_frame>
    <description>Change in serum LH reported in milli-international units per milliliter (mIU/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum follicular stimulating hormone (FSH)</measure>
    <time_frame>Days 7, 21, 28, 35, 49</time_frame>
    <description>Change in serum FSH reported in mIU/mL</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Hiv</condition>
  <condition>Prophylaxis</condition>
  <condition>Transgender</condition>
  <arm_group>
    <arm_group_label>Pre-Exposure Prophylaxis (PrEP) only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Truvada one tablet by mouth daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PrEP plus Gonadotropin Releasing Hormone (GnRH) Agonist</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Truvada one tablet by mouth daily Leuprolide 11.25 milligrams (mg) intramuscular (im) injection once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PrEP plus Low Dose Estrogen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Truvada one tablet by mouth daily Estradiol 1 milligram by mouth daily x 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PrEP plus High Dose Estrogen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Truvada one tablet by mouth daily Estradiol 6 milligrams (mg) by mouth daily x 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose Estrogen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Estradiol 6 mg by mouth daily x 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Truvada alone</intervention_name>
    <description>TDF/FTC 300 mg (milligrams) / 200 mg by mouth once daily</description>
    <arm_group_label>Pre-Exposure Prophylaxis (PrEP) only</arm_group_label>
    <other_name>tenofovir disoproxil fumarate/emtricitabine (TDF/FTC)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Truvada plus Leuprolide</intervention_name>
    <description>TDF/FTC 300mg/ 200 mg by mouth once daily Leuprolide 11.25 mg im once</description>
    <arm_group_label>PrEP plus Gonadotropin Releasing Hormone (GnRH) Agonist</arm_group_label>
    <other_name>Truvada plus Lupron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Truvada plus Estradiol 1 mg</intervention_name>
    <description>TDF/FTC 300mg/ 200 mg by mouth once daily Estradiol 1 mg by mouth once daily</description>
    <arm_group_label>PrEP plus Low Dose Estrogen</arm_group_label>
    <other_name>Truvada plus low dose estrogen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Truvada plus Estradiol 6 mg</intervention_name>
    <description>TDF/FTC 300mg/ 200 mg by mouth once daily Estradiol 3 mg by mouth twie daily</description>
    <arm_group_label>PrEP plus High Dose Estrogen</arm_group_label>
    <other_name>Truvada plus high dose estrogen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estradiol 6 mg alone</intervention_name>
    <description>Estradiol 3 mg by mouth twice daily</description>
    <arm_group_label>High Dose Estrogen</arm_group_label>
    <other_name>Estradiol 6 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18 years of age or older&#xD;
&#xD;
          2. Self-identifying as a transgender woman&#xD;
&#xD;
          3. Not currently taking any gender affirming hormonal therapy (GAHT) with a total&#xD;
             testosterone concentration of ≥ 200 ng/dL, or willing to abstain from feminizing&#xD;
             therapies (including estradiol, spironolactone, progesterone, etc.) until total total&#xD;
             testosterone concentrations are ≥ 200 ng/dL. Note: Testosterone may be retested every&#xD;
             2-4 weeks during screening to determine eligibility up to 6 weeks.&#xD;
&#xD;
          4. HIV-1 uninfected at screening as documented by Combo Ag/Ab HIV-1/HIV-2 immunoassay&#xD;
&#xD;
          5. Understand and agree to local STI reporting requirements&#xD;
&#xD;
          6. Able and willing to communicate in English&#xD;
&#xD;
          7. Able and willing to provide written informed consent to take part in the study&#xD;
&#xD;
          8. Able and willing to provide adequate information for locator purposes&#xD;
&#xD;
          9. Able and willing to participate in a directly observed study, which may occur in&#xD;
             person, using live streaming or a time stamped video?&#xD;
&#xD;
         10. Availability to return for all study visits, barring unforeseen circumstances&#xD;
&#xD;
         11. Willing to abstain from insertion of anything (drug, enema, penis, or sex toy) in&#xD;
             rectum for 72 hours before and 72 hours after each flexible sigmoidoscopy&#xD;
&#xD;
         12. Willing to refrain from aspirin and NSAID use for one week before and after each study&#xD;
             biopsy visit&#xD;
&#xD;
         13. Willing and able to use condoms for all Receptive Anal Intercourse (RAI) for the&#xD;
             duration of participation&#xD;
&#xD;
         14. Willing and able to participate in a directly observed study, which may occur in&#xD;
             person, using live streaming or a time stamped video&#xD;
&#xD;
         15. Has an identified healthcare provider for transgender health management&#xD;
&#xD;
         16. Agree not to participate in other research studies involving drugs and/or medical&#xD;
             devices for the duration of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Not currently on any PrEP regimen (e.g., Truvada®, tenofovir alafenamide/&#xD;
             emtricitabine)&#xD;
&#xD;
          2. History of chronic Hepatitis B infection, as documented by positive HBsAg at screening&#xD;
&#xD;
          3. ≥ Grade 2 laboratory abnormality at baseline as defined by Division of AIDS Table for&#xD;
             Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1 -&#xD;
             July 2017, and Addendum 3 (Rectal Grading Tables for Use in Microbicide Studies)&#xD;
&#xD;
          4. Significant colorectal symptom(s) as determined by medical history or by participant&#xD;
             self- report (including but not limited to presence of any unresolved injury,&#xD;
             infectious or inflammatory condition of the local mucosa, history of inflammatory&#xD;
             bowel disease, presence of symptomatic hemorrhoids, and presence of any painful&#xD;
             anorectal conditions that would be tender to manipulation)&#xD;
&#xD;
          5. At screening or within the past 2 months: participant-reported symptoms and/or&#xD;
             clinical or laboratory diagnosis of active rectal infection requiring treatment per&#xD;
             current Centers for Disease Control (CDC) guidelines or symptomatic urinary tract&#xD;
             infection (UTI). Infections requiring treatment include Chlamydia (CT), gonorrhea&#xD;
             (GC), syphilis, active herpes simplex virus (HSV) lesions, chancroid, genital sores or&#xD;
             ulcers, and, if clinically indicated, genital warts. Note that HSV seropositivity with&#xD;
             no active genital lesions is not an exclusion criterion. (Note: if an Sexually&#xD;
             Transmitted Infection (STI) apart from HIV is detected, the participant will be&#xD;
             referred for treatment and can be retested in 30 days and rescreened once.)&#xD;
&#xD;
          6. History of an underlying clinically significant cardiac arrhythmia or renal disease&#xD;
             (including creatinine clearance &lt; 60 mL/min using Cockcroft-Gault equation)&#xD;
&#xD;
          7. Serum phosphate &lt; 2.3 mg/dL&#xD;
&#xD;
          8. History of severe or recent cardiac or pulmonary event&#xD;
&#xD;
          9. History of significant gastrointestinal bleeding&#xD;
&#xD;
         10. Current use of warfarin or heparin or other anticoagulant medications associated with&#xD;
             increased risk for bleeding following mucosal biopsy (e.g., daily high dose aspirin&#xD;
             [&gt;81 mg], Non-steroidal anti-inflammatory drug [NSAIDs], or Pradaxa®)&#xD;
&#xD;
         11. Use of systemic or anorectal immunomodulatory medications within 4 weeks of enrollment&#xD;
             or planned use at any time during study participation&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>transgender women (biologic sex identified male at birth; identifying as female)</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark A Marzinke, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kate Marych, RN</last_name>
    <phone>(410) 955-1288</phone>
    <email>kdepros1@jhmi.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Johns Hopkins School of Medicine Drug Development Unit</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kate Marych, RN</last_name>
      <phone>410-955-1288</phone>
      <email>kdepros1@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Edward Fuchs, PA-C</last_name>
      <phone>(410)614-8762</phone>
      <email>ejfuchs@jhmi.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 15, 2021</study_first_submitted>
  <study_first_submitted_qc>February 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2021</study_first_posted>
  <last_update_submitted>March 8, 2021</last_update_submitted>
  <last_update_submitted_qc>March 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
    <mesh_term>Leuprolide</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Estrogens</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

